Lates News

According to AI FinTech News, open source securities released a research report on April 29th, giving Foshan Pharma (603998.SH) a buy rating. The main reasons for the rating include: 1) Revenue growth in cardiovascular and respiratory drug sales, with steady improvement in gross profit margin; 2) Continuous advancement in innovative research and development, improving long-term growth momentum. (Daily Economic News)